Outlook Therapeutics Completes Enrollment for NORSE EIGHT Clinical Trial
Outlook Therapeutics, Inc. (Nasdaq: OTLK) has reached an important milestone by completing enrollment for the NORSE EIGHT clinical trial. This trial focuses on treating wet age-related macular degeneration (wet AMD) with their innovative therapy, ONS-5010. Earlier this year, the company received regulatory approval for an ophthalmic formulation of bevacizumab in the European Union and the United Kingdom, making this news even more thrilling.
Details of the NORSE EIGHT Trial
The NORSE EIGHT trial is a randomized, controlled study involving patients who have recently been diagnosed with wet AMD. Participants are divided into two groups, with one receiving 1.25 mg of ONS-5010 and the other receiving 0.5 mg of ranibizumab through intravitreal injections at specified intervals. The primary objective is to assess the average change in best corrected visual acuity (BCVA) from the beginning of the trial to Week 8. The company plans to share the topline results from this trial in the fourth quarter of 2024.
CEO's Insights on the Progress
Russell Trenary, President and CEO of Outlook Therapeutics, expressed great satisfaction with this critical step toward resubmitting the Biologics License Application (BLA) for ONS-5010. He stated, "Completing this enrollment within eight months of our Special Protocol Assessment (SPA) from the FDA reflects the hard work of our clinical teams and the dedication of the participating patients. We believe ONS-5010 has the potential to greatly benefit retina specialists, patients, and payers, and we are excited to share the efficacy results soon."
Next Steps and Future Plans
Following previous collaborations with the FDA, Outlook Therapeutics held Type A meetings to discuss the Complete Response Letter (CRL) regarding ONS-5010. The FDA now supports the company in conducting the NORSE EIGHT non-inferiority study in treatment-naïve patients to strengthen their BLA resubmission process. With the trial now completed, Outlook aims to resubmit their application in the first quarter of 2025.
Commercialization Strategies
If everything goes as planned and ONS-5010 receives FDA approval, Outlook Therapeutics intends to market the product directly in the U.S. Additionally, they are exploring partnership opportunities for the commercial distribution of LYTENAVA™ (bevacizumab gamma) throughout Europe and other regions worldwide.
About ONS-5010 / LYTENAVA™
ONS-5010, also known as LYTENAVA™, is specifically designed for ocular use to treat wet AMD. Recently, the European Commission and the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorizations for this groundbreaking product, highlighting its potential to become a leading treatment option in the market.
Unique Mechanism of Action
LYTENAVA™ operates by neutralizing vascular endothelial growth factor (VEGF), which effectively reduces endothelial cell proliferation and the formation of new blood vessels, thus minimizing vascular leakage in the retina. This targeted strategy promises to significantly improve patient outcomes.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is committed to advancing therapies for retinal diseases and is focused on the commercialization of ONS-5010/LYTENAVA™, the first ocular formulation of bevacizumab approved for wet AMD in the EU and UK. The company aims to launch this innovative product in the first half of 2025, offering hope to patients affected by retinal conditions.
Frequently Asked Questions
What is the purpose of the NORSE EIGHT trial?
The NORSE EIGHT trial aims to evaluate how effective ONS-5010 is in treating patients with wet AMD compared to ranibizumab.
When can we expect the results from the NORSE EIGHT trial?
Topline results from the NORSE EIGHT trial are anticipated to be reported in the fourth quarter of 2024.
What does FDA approval mean for Outlook Therapeutics?
FDA approval would enable Outlook Therapeutics to commercialize ONS-5010 in the U.S., marking it as the first approved ophthalmic formulation of bevacizumab for retinal diseases.
What is the mechanism of action for ONS-5010?
ONS-5010 functions by targeting and neutralizing VEGF, which prevents the growth of new blood vessels and reduces retinal leakage.
What are Outlook Therapeutics' plans following the trial results?
After the trial results are available, Outlook plans to resubmit the BLA for ONS-5010 in early 2025 and will consider commercialization strategies based on the outcomes.
